文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

BCR-ABL阴性骨髓增殖性肿瘤的免疫景观:炎症、感染与免疫治疗机遇

The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.
PubMed 文献 · Br J Haematol · 2021-10-07

本文综述BCR-ABL阴性骨髓增殖性肿瘤(MPN)的免疫景观,包括真性红细胞增多症、原发性血小板增多症和骨髓纤维化。免疫系统失调是关键病理环节,支持克隆演化、介导症状并导致不同程度免疫受损。靶向免疫功能障碍是重要治疗策略,但需更精细研究以区分亚型感染易感性差异及炎症赋予克隆竞争优势的机制。

要点

  • 免疫失调是MPN病理核心,支持克隆演化并介导症状。
  • MPN患者存在不同程度免疫受损,感染易感性因亚型而异。
  • 靶向免疫功能障碍是MPN重要治疗策略,免疫调节疗法正在涌现。

核心结论

  • 免疫系统失调是BCR-ABL阴性MPN病理的关键环节,支持克隆演化、介导症状并导致免疫受损。
  • 靶向免疫功能障碍是MPN的重要治疗策略,但需更精细研究以区分亚型感染易感性差异及炎症赋予克隆竞争优势的机制。

研究设计与样本

  • 本文为综述,聚焦BCR-ABL阴性MPN患者的免疫景观,包括炎症在发病机制中的作用、感染易感性和治疗性免疫调节新策略。

主要发现

  • BCR-ABL阴性MPN由造血干细胞基因突变引发克隆扩增和血细胞及其祖细胞过度产生。
  • MPN包括真性红细胞增多症、原发性血小板增多症和骨髓纤维化,具有重叠但独特的分子、实验室和临床特征。
  • 免疫系统失调支持克隆演化、介导症状并导致不同程度免疫受损。

临床怎么用

  • 临床应关注MPN患者的免疫功能障碍,评估感染风险并考虑免疫调节治疗策略。

局限性

  • 需进一步详细研究以更精确描绘MPN免疫扰动,确定感染易感性在临床亚型间的差异及原因,并更好理解炎症如何为MPN克隆提供竞争优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breakpoint cluster region-Abelson (BCR-ABL) negative myeloproliferative neoplasms (MPNs) are chronic myeloid neoplasms initiated by the acquisition of gene mutation(s) in a haematopoietic stem cell, leading to clonal expansion and over-production of blood cells and their progenitors. MPNs encompass a spectrum of disorders with overlapping but distinct molecular, laboratory and clinical features. This includes polycythaemia vera, essential thrombocythaemia and myelofibrosis. Dysregulation of the immune system is key to the pathology of MPNs, supporting clonal evolution, mediating symptoms and resulting in varying degrees of immunocompromise. Targeting immune dysfunction is an important treatment strategy. In the present review, we focus on the immune landscape in patients with MPNs - the role of inflammation in disease pathogenesis, susceptibility to infection and emerging strategies for therapeutic immune modulation. Further detailed work is required to delineate immune perturbation more precisely in MPNs to determine how and why vulnerability to infection differs between clinical subtypes and to better understand how inflammation results in a competitive advantage for the MPN clone. These studies may help shed light on new designs for disease-modifying therapies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Strickland M, Quek L, Psaila B, et al. The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy. Br J Haematol. 2021. PMID: 34618358. doi:10.1111/bjh.17850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。